Sally Bridget Lawlor net worth and biography

Sally Lawlor Biography and Net Worth

Sally Lawlor joined Quoin Pharmaceuticals in August 2025 as Chief Financial Officer. She brings 20 years of finance experience across Big Four accounting and senior roles in public and private companies. Most recently, she held senior finance positions at Sebela Pharmaceuticals, overseeing audited financials under U.S. GAAP and IFRS, FP&A, budgeting, cash management, and global tax compliance. Previously, she served at Aptiv Plc as EMA Tax Lead and Director of Global Tax Planning. Earlier, Lawlor spent over a decade with KPMG advising multinational clients in the pharmaceutical and technology sectors. She is a Fellow of Chartered Accountants Ireland, a member of the Irish Taxation Institute, and holds a bachelor’s degree in Law and German from University College Cork.

What is Sally Bridget Lawlor's net worth?: The estimated net worth of Sally Bridget Lawlor is at least $50.43 thousand as of August 31st, 2026. Ms. Lawlor owns 10,684 shares of Quoin Pharmaceuticals stock worth more than $50,428 as of October 7th. This net worth estimate does not reflect any other investments that Ms. Lawlor may own. Learn More about Sally Bridget Lawlor's net worth.
How do I contact Sally Bridget Lawlor?: The corporate mailing address for Ms. Lawlor and other Quoin Pharmaceuticals executives is 23 Hata'as Street, Kfar Saba, 44425. Quoin Pharmaceuticals can also be reached via phone at +97299741444 and via email at [email protected]. Learn More on Sally Bridget Lawlor's contact information.
Has Sally Bridget Lawlor been buying or selling shares of Quoin Pharmaceuticals?: Sally Bridget Lawlor has not been actively trading shares of Quoin Pharmaceuticals in the last ninety days. Most recently, on Monday, August 31st, Sally Bridget Lawlor bought 10,244 shares of Quoin Pharmaceuticals stock. The stock was acquired at an average cost of $4.88 per share, with a total value of $49,990.72. Following the completion of the transaction, the chief financial officer now directly owns 10,684 shares of the company's stock, valued at $52,137.92. Learn More on Sally Bridget Lawlor's trading history.
Who are Quoin Pharmaceuticals' active insiders?: Quoin Pharmaceuticals' insider roster includes Denise Carter (COO), Anthony Culverwell (Director), Gordon Dunn (CFO), Dennis Langer (Director), Sally Lawlor (CFO), and Michael Myers (CEO). Learn More on Quoin Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Quoin Pharmaceuticals?: In the last twelve months, Quoin Pharmaceuticals insiders bought shares 5 times. They purchased a total of 72,522 shares worth more than $408,606.08. The most recent insider tranaction occured on August, 31st when COO Denise P. Carter bought 20,490 shares worth more than $99,991.20. Insiders at Quoin Pharmaceuticals own 11.2% of the company. Learn More about insider trades at Quoin Pharmaceuticals.
Information on this page was last updated on 8/31/2026.

Sally Bridget Lawlor Insider Trading History at Quoin Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/31/2026	Buy	10,244	$4.88	$49,990.72	10,684

Sally Bridget Lawlor Buying and Selling Activity at Quoin Pharmaceuticals

Quoin Pharmaceuticals Company Overview

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Today's Range

Now: $4.62

$4.51

$4.79

50 Day Range

MA: $5.73

$4.26

$7.87

2 Week Range

Now: $4.62

$3.25

$41.80

Volume

3,610 shs

Average Volume

292,420 shs

Market Capitalization

$9.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56